Idera Pharmaceuticals To Present Positive Phase 1 Trial Results On TLR Antagonist IMO-8400 For The Treatment Of Autoimmune Diseases At FOCIS 2013

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present positive Phase 1 trial results on IMO-8400, a selective inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment of autoimmune diseases, at the 13 th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.

Details of the presentation are as follows:
     

Date:
Saturday, June 29, 2013

Time:
6:30-7:45pm ET

Location:
Commonwealth Hall, The Boston Seaport Hotel

Abstract Number:
S.85

Title:
Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9
 

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For more information, visit http://www.iderapharma.com.

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX